Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.46 |
| ▸ | PARP1 | P09874 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | PAK4 | O96013 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5471194 | 0.79 | MEN1 (0.60) | MEN1KMT2AHTTMAPTMAPK14 | |
| SCHEMBL25379627 | 0.78 | CDK4 (0.60) | MEN1KMT2AHTTMAPTMAPK14 | |
| SCHEMBL838945 | 0.76 | MAPK14 (0.41) | MEN1KMT2AHTTMAPTMAPK14 | |
| SCHEMBL838719 | 0.74 | MAPK14 (0.42) | MEN1KMT2AHTTMAPTMAPK14 | |
| SCHEMBL4697615 | 0.73 | HTT (0.53) | MEN1KMT2AHTTMAPTALDH1A1 | |
| SCHEMBL2077064 | 0.73 | MAPT (0.59) | MEN1KMT2AHTTMAPTALDH1A1 | |
| SCHEMBL5611717 | 0.70 | HTT (0.45) | MEN1KMT2AHTTMAPTALDH1A1 | |
| SCHEMBL21525564 | 0.70 | HTT (0.59) | MEN1KMT2AHTTMAPTALDH1A1 | |
| SCHEMBL32668630 | 0.70 | HTT (0.59) | MEN1KMT2AHTTMAPTALDH1A1 | |
| SCHEMBL5611735 | 0.69 | HTT (0.44) | MEN1KMT2AHTTMAPTMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8071608-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| US-8071608-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| US-8071608-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| EP-2324028-A2 | THERAPEUTIC AGENTS 414 | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010116176-A1 | PYRAZOLO [4, 5-E] PYRIMIDINE DERIVATIVE AND ITS USE TO TREAT DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010116176-A1 | PYRAZOLO [4, 5-E] PYRIMIDINE DERIVATIVE AND ITS USE TO TREAT DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261733-A1 | THERAPEUTIC AGENTS 927 | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261733-A1 | THERAPEUTIC AGENTS 927 | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261733-A1 | THERAPEUTIC AGENTS 927 | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | GCK, GCKR, GPR119 | MEN1 2410/4885KMT2A 4136/4885HTT 2010/4885 |
| US-20100261733-A1 | THERAPEUTIC AGENTS 927 | GCK, GCKR, GALK1 | MEN1 2935/4885KMT2A 3031/4885HTT 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.